Starpharma, Merck collaborate on new ADCs

By The Science Advisory Board staff writers

February 12, 2021 -- Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's proprietary DEP dendrimer drug delivery technology.

DEP ADCs exploit the potential of Starpharma's DEP technology to provide enhanced characteristics including greater homogeneity, site specific attachment, and higher antibody ratio, compared to conventional ADC approaches, according to the firm.

In previous preclinical studies, DEP ADCs have shown significant tumor regression and outperformed other approved drugs in human ovarian cancer models. Financial details of the agreement were not disclosed.

Sorrento subsidiary to develop ADC cancer therapies
Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for...
Lantern Pharma, Califia Pharma to launch ADC program
Lantern Pharma is launching the development of an antibody-drug conjugate (ADC) program through an evaluation and potential development agreement with...
Tubulis, WuXi partner to bring antibody-drug conjugates to clinical trials
Tubulis and WuXi Biologics have announced a strategic collaboration to manufacture Tubulis' next-generation antibody-drug conjugates toward investigational...
Seattle Genetics, Merck partner on 2 oncology drug programs
Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately,...
MilliporeSigma expands antibody-drug conjugate manufacturing
MilliporeSigma is expanding its high-potent active pharmaceutical ingredient and antibody-drug conjugate manufacturing capabilities with a $65 million...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter